One year survival is less than 50% compared to figures above 90% in patients with cholestatic or alcoholic liver disease.
Active pre-transplant viral replication - HBeAg +ve or HBV DNA +ve - is associated with a poorer prognosis.
Post-transplant reinfection occurs in nearly all cases. The likelihood is greatest in patients who were HBV DNA +ve at the time of transplantation.
High dose immunoglobulin perioperatively and postoperatively is the most effective way of delaying and preventing HBV recurrence.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page